Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.
Mr. Crowley is involved with several charitable and community organizations, including serving as president of the National Tay-Sachs and Allied Diseases Association. He is also on the Research Advisory Board of the national Muscular Dystrophy Association and the Board of Directors of St. Peter’s University Hospital. Mr. Crowley’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease – a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show.
Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).
Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University’s School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.
